Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sensei Biotherapeutics, Inc.

11.70
-5.8750-33.43%
Post-market: 12.000.3000+2.56%19:58 EDT
Volume:781.00K
Turnover:12.10M
Market Cap:14.76M
PE:-0.55
High:17.55
Open:15.05
Low:10.52
Close:17.58
52wk High:18.35
52wk Low:5.00
Shares:1.26M
Float Shares:828.30K
Volume Ratio:18.29
T/O Rate:94.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.3036
EPS(LYR):-24.0130
ROE:-67.47%
ROA:-36.75%
PB:0.54
PE(LYR):-0.49

Loading ...

Sensei Biotherapeutics reports results from Phase 1/2 trial of solnerstotug

TIPRANKS
·
Yesterday

Sensei Biotherapeutics Unveils New Data on Solnerstotug, a First-in-Class VISTA-Targeting Immunotherapy Designed to Minimize Toxicity and Improve Tumor Response

Reuters
·
Yesterday

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

GlobeNewswire
·
Yesterday

Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations

Dow Jones
·
Yesterday

Sensei Biotherapeutics Shares Halted for Volatility, Last up 34%

THOMSON REUTERS
·
Yesterday

Sensei Biotherapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Yesterday

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

GlobeNewswire
·
Sep 23

Sensei Biotherapeutics Inc : H.c. Wainwright Adjusts Target Price to $30 From $5 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Aug 05

Sensei Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 05

Sensei Biotherapeutics Q2 EPS $(3.91) Beats $(5.60) Estimate

Benzinga
·
Aug 05

Sensei Biotherapeutics Inc - Expects Cash to Fund Operations Into Q2 2026

THOMSON REUTERS
·
Aug 05

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 05

Sensei Biotherapeutics Inc expected to post a loss of $5.60 a share - Earnings Preview

Reuters
·
Aug 01

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

GlobeNewswire
·
Jul 30

Sensei Biotherapeutics Regains Compliance with Nasdaq Listing Rule After Meeting Bid Price Requirement

Reuters
·
Jul 10

Harrow Inc. Appoints Mike Biega as New Vice President of Investor Relations and Communications Amid Leadership Transition

Reuters
·
Jun 18

Sensei Biotherapeutics to Implement 1-for-20 Reverse Stock Split

MT Newswires Live
·
Jun 13

BRIEF-Sensei Biotherapeutics Announces 1-For-20 Reverse Stock Split

Reuters
·
Jun 13

Sensei Biotherapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Jun 02

Sensei Biotherapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
May 23